Duffy-null effect on chemotherapy dosing in people of African or Middle Eastern descent
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how a specific genetic trait (Duffy-null) affects white blood cell counts and chemotherapy dosing in people of Middle Eastern or African descent. The goal is to help doctors determine the right chemotherapy dose to reduce side effects while still being effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You are of Middle Eastern or African descent.
- You have been diagnosed with a solid organ cancer (like melanoma) and have not yet received chemotherapy. Surgery alone is acceptable.
- You do not have an active uncontrolled infection requiring IV antibiotics.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if changing the dose of certain chemotherapy drugs can help people with a genetic trait called Duffy null avoid side effects like low white blood cell counts. It is for people with multiple myeloma or triple-negative breast cancer starting specific treatments.
This trial checks if adjusting the dose of chemotherapy drugs 5-FU or capecitabine based on your DPYD genetic results can improve safety and effectiveness. It’s for people with cancer who are about to start these drugs for the first time.
This study looks at how your genes affect the way your body handles the chemotherapy drug capecitabine when it's taken with oxaliplatin. The goal is to understand if certain genetic differences can impact drug levels, which may help personalize treatment in the future.
This trial tests a new drug called DXC018 for people with advanced solid tumors that have not responded to standard treatments or for whom no standard treatment exists. The goal is to see if the drug can shrink or slow the growth of these tumors.
This study looks at how safe and effective the drug T-DXd (trastuzumab deruxtecan) is for Chinese patients with a specific type of lung cancer that has a HER2 mutation. It helps understand if this treatment works well in real-world settings.
This trial tests a chemotherapy drug (trifluridine/tipiracil) in people with metastatic colorectal or gastroesophageal cancer who have a DPD deficiency. DPD deficiency means your body may have trouble breaking down certain chemotherapy drugs, which can lead to serious side effects. This study aims to see if this drug is safe and effective for you.
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.